# Enekinragene inzadenovec PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/enekinragene-inzadenovec

> The FDA approved enekinragene inzadenovec, sponsored by Pacira BioSciences, Inc. (PCRX), on Feb 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | enekinragene inzadenovec |
| Codes | PCRX-201 |
| Sponsor | Pacira BioSciences, Inc. (PCRX) https://sec-api.dev/companies/pcrx/catalysts |
| Indications | oa of the knee, osteoarthritis, or oa, of the knee |
| Modality | gene_therapy |
| FDA designations | rmat |

## Timeline

### Feb 2024: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-08-05, last confirmed 2025-08-05.
- SEC Form 10-Q (accession 0001396814-25-000102): "These increases were partially offset by the completion of pre-commercial scale-up activities of our enhanced, larger-scale EXPAREL manufacturing capacity at our Science Center Campus in San Diego, California, which the FDA approved in February 2024 and was placed into service in July 2024." https://www.sec.gov/Archives/edgar/data/1396814/000139681425000102/pcrx-20250630.htm

### Feb 2025: trial start

- Status: scheduled. Date confidence: month. Stage: 2.
- First seen 2025-02-27, last confirmed 2025-02-27.
- SEC Form 10-K (accession 0001396814-25-000041): "Table of Contents provides financial benefits with the elimination of future development and sales-based milestones including a $4.5 million milestone payment due upon initiation of the Phase 2 clinical trial of PCRX-201 that opened enrollment in February 2025." https://www.sec.gov/Archives/edgar/data/1396814/000139681425000041/pcrx-20241231.htm

### Apr 2025: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: osteoarthritis, or OA, of the knee.
- First seen 2025-05-08, last confirmed 2025-05-08.
- SEC Form 10-Q (accession 0001396814-25-000061): "•In April 2025, we announced that the first patient was dosed in our Phase 2 ASCEND study evaluating the safety and efficacy of PCRX-201 for the treatment of OA of the knee." https://www.sec.gov/Archives/edgar/data/1396814/000139681425000061/pcrx-20250331.htm
- Press release filed with the SEC (EX-99) (accession 0001396814-25-000060): "In April 2025, patient dosing began in the Phase 2 ASCEND study of PCRX-201 (enekinragene inzadenovec) for the treatment of osteoarthritis, or OA, of the knee." https://www.sec.gov/Archives/edgar/data/1396814/000139681425000060/pcrx-3312025x991.htm

### late 2026: interim data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-08-05, last confirmed 2025-11-06.
- SEC Form 10-Q (accession 0001628280-25-050176): "We remain on track to report results from a pre-specified interim analysis before the end of 2026." https://www.sec.gov/Archives/edgar/data/1396814/000162828025050176/pcrx-20250930.htm
- Press release filed with the SEC (EX-99) (accession 0001396814-25-000100): "The company remains on track to complete enrollment in Part A of the study before the end of 2025 and report results from an interim analysis before the end of 2026." https://www.sec.gov/Archives/edgar/data/1396814/000139681425000100/pcrx-6302025x991.htm

## Same indication

- [LTG-321](https://sec-api.dev/pdufa/ltg-321) (LTGO)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/enekinragene-inzadenovec.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Enekinragene inzadenovec PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/enekinragene-inzadenovec

```bibtex
@misc{secapidev_pdufa_enekinragene_inzadenovec_20261116,
  title        = {Enekinragene inzadenovec PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/enekinragene-inzadenovec}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_enekinragene_inzadenovec_20261116","title":"Enekinragene inzadenovec PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/enekinragene-inzadenovec","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
